Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | HTR1D | P28221 | 3/20 | 0.41 |
| ▸ | HTR1B | P28222 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | HTR1F | P30939 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | HTR1E | P28566 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212533 | 0.89 | LMNA (0.42) | HTR6LMNAHTR1AHTR1DHTR1B | |
| SCHEMBL3199222 | 0.88 | LMNA (0.42) | HTR6LMNAHTR1AHTR1DHTR1B | |
| SCHEMBL3218370 | 0.84 | HTR6 (0.45) | HTR6LMNAHTR1AHTR1DHTR1B | |
| SCHEMBL3207495 | 0.82 | HTR6 (0.40) | HTR6HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL3202550 | 0.82 | PKM (0.45) | HTR6HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL3207395 | 0.81 | RAB9A (0.43) | HTR6HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL3212422 | 0.81 | HTR6 (0.46) | HTR6HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL3195017 | 0.81 | HTR6 (0.49) | HTR6LMNA | |
| SCHEMBL3182634 | 0.81 | HTR6 (0.49) | HTR6LMNA | |
| SCHEMBL3182785 | 0.80 | HTR6 (0.49) | HTR6LMNATSHRCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029629-A1 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029629-A1 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010011546-A2 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011546-A2 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029629-A1 | ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1A, HTR5A | HTR6 1/4885LMNA 2649/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.